iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.66 to $0.75
• 50-Day Range: $0.57 to $1.03
• 52-Week Range: N/A
• Volume: 962,542 shs
• Average Volume: 113,212 shs
• Market Capitalization: $11.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.45 at the beginning of 2025. Since then, IBIO stock has decreased by 72.3% and is now trading at $0.6780.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEMKT:IBIO) issued its earnings results on Monday, November, 15th. The company reported ($20.00) earnings per share for the quarter, topping the consensus estimate of ($25.00) by $5.00. The company had revenue of $0.21 million for the quarter.

When did iBio's stock split?

iBio shares reverse split before market open on Wednesday, November 29th 2023.The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Vaxart (VXRT), Plug Power (PLUG), Tesla (TSLA), Advanced Micro Devices (AMD) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 8/15/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: (302) 355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.01 million
• Net Margins: N/A
• Pretax Margin: -41,546.00%
• Return on Equity: -150.59%
• Return on Assets: -52.83%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 0.91
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $375 thousand
• Price / Sales: 29.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.64 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 16,519,000
• Free Float: 3,445,000
• Market Cap: $11.20 million
• Optionable: N/A
• Beta: 0.60